Liver Transplantation for Pediatric Hepatocellular Carcinoma: A Systematic Review.
Christos D KakosIoannis A ZiogasCharikleia D DemiriStepan M EsagianKonstantinos P EconomopoulosDimitrios P MorisGeorgios TsoulfasSophoclis P AlexopoulosPublished in: Cancers (2022)
Liver transplantation (LT) is the only potentially curative option for children with unresectable hepatocellular carcinoma (HCC). We performed a systematic review of the MEDLINE, Scopus, Cochrane Library, and Web of Science databases (end-of-search date: 31 July 2020). Our outcomes were overall survival (OS) and disease-free survival (DFS). We evaluated the effect of clinically relevant variables on outcomes using the Kaplan-Meier method and log-rank test. Sixty-seven studies reporting on 245 children undergoing LT for HCC were included. DFS data were available for 150 patients and the 1-, 3-, and 5-year DFS rates were 92.3%, 89.1%, and 84.5%, respectively. Sixty of the two hundred and thirty-eight patients (25.2%) died over a mean follow up of 46.8 ± 47.4 months. OS data were available for 222 patients and the 1-, 3-, and 5-year OS rates were 87.9%, 78.8%, and 74.3%, respectively. Although no difference was observed between children transplanted within vs. beyond Milan criteria ( p = 0.15), superior OS was observed in children transplanted within vs. beyond UCSF criteria ( p = 0.02). LT can yield favorable outcomes for pediatric HCC beyond Milan but not beyond UCSF criteria. Further research is required to determine appropriate LT selection criteria for pediatric HCC.
Keyphrases
- end stage renal disease
- newly diagnosed
- young adults
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- public health
- type diabetes
- emergency department
- patient reported outcomes
- big data
- metabolic syndrome
- electronic health record
- deep learning
- locally advanced
- rectal cancer
- patient reported
- drug induced